Phase I
It was another busy week for clinical trials. Here’s a look.
Imugene Limited, a clinical stage immuno-oncology company, announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti-cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.
Adrenomed AG, the vascular integrity company, announced the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock.
It was a moderately busy week for clinical trial news. Here’s a look.
PDS Biotechnology Corporation announced that it has reviewed limited available patient clinical outcome data from its previously reported Phase 1 study.
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Primary results showed significantly greater reduction in blood sugar levels over 26 weeks after switching to Soliqua® / Suliqua® 1 vs staying on daily or weekly GLP-1 receptor agonist
PRESS RELEASES